Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Effects of a decaffeinated green coffee extract on body weight control by regulation of glucose metabolism

a green coffee and glucose metabolism technology, applied in the field of dietary supplements comprising green coffee extract, can solve the problems of increasing and achieve the effects of reducing glycemia, reducing glycemia, and reducing the risk of cardiovascular diseas

Active Publication Date: 2015-03-12
NATUREX SA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0017]Broadly, the present invention is directed to methods of using green coffee extract, such as Svetol® brand green coffee extract (commercially available from NATUREX S.A., Avignon France), to inhibit the Glc-6-Pase system, reduce glycemia and promote reduced body fat, increase Muscle Mass / Fat Mass ratio (MM / FM) in the body, and reduce the body weight and body mass index (BMI) in humans. One aspect of the invention is directed to a method of improving body weight in humans and reducing the risk of Type 2 diabetes (T2D) by administering an amount of green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 5-caffeoylquinic acid (5-CQA) to total chlorogenic acids (tCGA) (5-CQA / tCGA) of from about 0.2 and 0.3. More preferably, the concentration of tCGA is greater than about 45% and the concentration of 5-CQA is less than about 10%. A preferred method of administration consists of administering between about 200 mg and about 1,000 mg per day, more preferably administering about 400 mg per day. In one embodiment, the green coffee extract is administered to a subject in a dosage of between about 200 mg and about 1,000 mg per day of green coffee extract.
[0019]The inventors believe they are the first to have discovered that one can use a green coffee extract for the inhibition of the Glc-6-Pase system. The inhibition of the Glc-6-Pase system is favored by the ratio existing between 5-CQA and tCGA in the green coffee extract. For the first time, it is demonstrated that not only 5-CQA inhibits the Glc-6-Pase system, but also other CGA present in the green coffee extract. This specially designed green coffee extract is more effective in inhibiting the Glc-6-Pase system than the combination of isolated CGA, evidencing a greater level of synergy between all natural CGA present in the extract.
[0021]In one embodiment of the invention, the bioavailability of CGA in humans is defined from the specially designed green coffee extract of the present invention. Data on the bioavailability of CGA from green coffee in humans was previously nonexistent. The special composition in the green coffee extract allows that three CQA, three diCQA and caffeic, ferulic, isoferulic and p-coumaric acids are bioavailable in plasma; and 4-CQA, 5-CQA and sinapic, p-hydroxybenzoic, gallic, vanillic, dihydrocaffeic, caffeic, ferulic, isoferulic, and p-coumaric acids in urine. Therefore, the CGA in the green coffee extract, which is also able to inhibit the Glc-6-Pase system activity, is bioavailable in humans as evidenced in plasma and urine.
[0022]In another embodiment of the invention, a green coffee extract (Svetol® green coffee extract, NATUREX) is applied and able to reduce glycemia in humans.
[0023]In another embodiment of the invention, a green coffee extract (Svetol® green coffee extract, NATUREX) is applied and able to reduce body fat in humans.
[0025]In another embodiment of the invention, a green coffee extract (Svetol® green coffee extract, NATUREX) is applied and able to reduce body weight in humans.

Problems solved by technology

In addition, the choice of raw material and the extraction conditions provide an extract containing no cafestol or kahweol, constituents of coffee which can increase the risk of cardiovascular disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Effects of a decaffeinated green coffee extract on body weight control by regulation of glucose metabolism
  • Effects of a decaffeinated green coffee extract on body weight control by regulation of glucose metabolism
  • Effects of a decaffeinated green coffee extract on body weight control by regulation of glucose metabolism

Examples

Experimental program
Comparison scheme
Effect test

example 1

In some embodiments, the green coffee extract comprises, Nutritional profiles of a green coffee extract (Svetol® green coffee extract, NATUREX). Nutritional analyses were conducted according to the European pharmacopoeia. Table 4 shows the nutritional value of the green coffee extract used in the examples reported herein (Svetol® green coffee extract, NATUREX).

[0049]

TABLE 4Nutritional profile of the green coffee extract (Svetol ® greencoffee extract, NATUREX).CompoundConcentrationLoss of drying [JO Mar. 11, 1977] 5%Proteins (Nx6.25) [JO Mar. 11, 1977] 9%Lipids [JO Mar. 11, 1977] 1%Ash [JO Mar. 11, 1977]10%Soluble sugars [JO Mar. 11, 1977]24%Caffeine [HPLC] 1%Total polyphenols [Folin-Ciocalteau]50%(tCGA) Total chlorogenic acids [HPLC]45%(5 CQA) 5-cajfeoylquinic acid [HPLC]>10% Cafestol [HPLC]Kahweol [HPLC]TOTAL100% 

[0050]The ratio between 5-caffeoylquinic acid (5-CQA) and total chlorogenic acids (tCGA) (5-CQA / tCGA in Table 4) of the green coffee extract (Svetol® green coffee extract,...

example 2

HPLC Chromatogram of the Green Coffee Extract (Svetol® Green Coffee Extract, NATUREX)

[0051]The high-pressure liquid chromatography chemical fingerprint for a green coffee extract (Svetol® green coffee extract, NATUREX) is presented in FIG. 6. The method for performing this analysis was as follows: HPLC-DAD was achieved using a column RP-C18 (5 μm-250×4.6 mm) at 55° C. The flow rate was 0.8 mL / min, and the elution was monitored at 330 nm. The mobile phases were (A) distilled water+H3PO4 0.002M, and (B) acetonitrile. A solution of 100% A was maintained during 8 min, increased by linear gradient to 35% A and 65% B by volume after 35 min total time; followed by a linear gradient of 100% A after maintaining this composition for 10 min; the system was then re-equilibrated to the initial composition. The content of CGA from 10 batches of green coffee extract (Svetol® green coffee extract, NATUREX) reported as mean±standard deviation (SD) is shown in Table 5.

TABLE 5Chlorogenic acids (CGA) o...

example 3

Composition of Total Chlorogenic Acids (tCGA) and 5-Caffeoylquinic Acid (5-CQA) in Several Coffee Extracts

[0052]Table 6 shows the composition of chlorogenic acids (tCGA) and 5-caffeoylquinic acid (5-CQA), as well as the ratio 5-CQA / tCGA, of several commercial extracts. All samples were analyzed using the HPLC method described in Example 2. The last two rows include the values of the green coffee extract described in this invention (Svetol® green coffee extract, NATUREX).

TABLE 6Composition of total chlorogenic acids (tCGA) and 5-caffeoylquinicacid (5-CQA) in several coffee extracts.tCGARatio 5-CQA / Coffee extract(HPLC)5-CQAtCGASpecieSvetol ®, Naturex146.4112.550.27C. robustaCommercial sample 15.572.20.39C. arabicaCommercial sample 26.072.20.36C. arabicaCommercial sample 35.551.980.36C. arabicaCommercial sample 450240.48C. arabicaCommercial sample 535180.51C. arabicaCommercial sample 645190.42C. arabicaCommercial sample 72750.19C. arabicaCommercial sample 853 / C. arabica(Batch 1)Commerc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA / tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.

Description

[0001]This application is a continuation-in-part and claims the benefit of a non-provisional U.S. patent application Ser. No. 12 / 263,292 filed on Oct. 31, 2008.FIELD OF THE INVENTION[0002]The present invention relates to dietary supplements comprising a green coffee extract and methods relating to the administration of green coffee extract.BACKGROUND OF THE INVENTION[0003]The prevalence of obesity (BMI≧30 kg / m2) continues to be a health concern for adults, children and adolescents in the United States. Data from the NHANES survey shows that among adult men the prevalence of obesity increased from 31.1% in 2003-04 to 32.2% in 2007-08, a small but not statistically significant change. Among adult women, the prevalence of obesity increased from 33.2% in 2003-04 to 35.5% in 2007-08, again a small but not significant change (Ogden et al. Gastroenterology 2007; 132 (6):2087-2102; Flegal et al. JAMA 2009; 303 (3):235-241). In Europe, the prevalence of obesity has increased by 10 to 38%, de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A23L1/30A23L1/302A23L1/304A23L1/28A23L33/15
CPCA61K31/235A61K36/74A61K45/06
Inventor IBARRA, ALVINROLLER, MARCDIKANSKY, JACQUES
Owner NATUREX SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products